Form 4: CRISPR Therapeutics GC Sells Shares for Tax

CRISPR Therapeutics General Counsel James R. Kasinger acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations.

Summary

• James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reported transactions involving the company's common shares.
• On October 13, 2025, 2,114 common shares were acquired due to the vesting of restricted stock units (RSUs).
• On October 14, 2025, 1,076 common shares were sold at a price of $66.6 per share.
• This sale was non-discretionary, mandated by the company's RSU Settlement Policy to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Kasinger beneficially owns 83,402 common shares.
• The reported beneficial ownership includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
• The restricted stock unit award was originally granted on October 13, 2023, for 6,340 Common Shares, vesting in three equal annual installments.

Sentiment

Score: 5

Explanation: The filing details a routine insider transaction (RSU vesting and tax-related sale) which is a common occurrence for executives and does not typically indicate a discretionary change in sentiment towards the company's prospects.

Positives

• The vesting of restricted stock units indicates continued executive compensation and retention, aligning management interests with shareholder value.

Negatives

• A reduction in direct insider share ownership occurred, although it was a non-discretionary sale for tax purposes rather than a voluntary divestment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction involves a minor, non-discretionary sale of shares, which is unlikely to have a significant impact on the company's stock price or investor sentiment.
• Employees: The vesting and tax-related sale of RSUs are standard components of executive compensation packages, reflecting the company's established equity incentive plans.

Next Steps

• The remaining one-third of the restricted stock unit award (2,113 shares) is scheduled to vest on October 13, 2026.

Key Dates

Recommendation

The filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent non-discretionary sale to cover tax obligations. This type of transaction is common for executives and does not typically signal a change in the company's fundamental outlook or the insider's long-term conviction. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

CRISPR Therapeutics, CRSP, Insider Transaction, Form 4, Stock Sale, RSU Vesting, James R. Kasinger, General Counsel, Executive Compensation